Enter assignee name

CIPO Patents = 3

EPO Patents = 3

Trademarks = 38

Forward Citations = 9

Loading Chart...

34 inventors (with patents filed for the assignee):

Karen Kozarsky (3 out of 10 patents)

Walter C Low (2 out of 13 patents)

R Scott McIvor (2 out of 10 patents)

4. Carolyn Ann Fairbanks (2 out of 4 patents)

5. Claire G Zhang (2 out of 2 patents)

6. Franz M Gerner (2 out of 2 patents)

7. Lalitha R Belur (2 out of 2 patents)

8. Nicholas M Boulis (1 out of 3 patents)

9. Shunji Tomatsu (1 out of 14 patents)

10. Rickey Robert Reinhardt (1 out of 1 patent)

11. Stephen Yoo (1 out of 1 patent)

12. Curran Matthew Simpson (1 out of 1 patent)

13. Zhuchun Wu (1 out of 1 patent)

14. Stephen Joseph Pakola (1 out of 1 patent)

15. Olivier Danos (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 12365865 - Scalable clarification process for recombinant AAV production (2025-07-22),

2. 12247213 - Treatment of mucopolysaccharidosis IVA (2025-03-11),

3. 12121567 - Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase (2024-10-22),

4. 12070702 - Anion exchange chromatography for recombinant AAV production (2024-08-27),

5. 12070510 - Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid (2024-08-27),

6. 11986515 - Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) (2024-05-21),

7. 11613739 - Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells (2023-03-28),

8. 9827295 - Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase (2017-11-28),

Regenxbio Inc. is a leading clinical-stage biotechnology company focused on the development, commercialization, and licensing of genetic therapies for the treatment of rare genetic diseases. With its proprietary gene therapy platform, Regenxbio is dedicated to improving the lives of patients with debilitating conditions by addressing the underlying genetic cause of their diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

8 Patents

#75 in Rockville, MD

#488 in Maryland

#34,831 in US

Rockville, MD, United States of America

Regenxbio Inc.